QGEN (Qiagen) stock outlook for 2026. A deep qualitative look at the razor-and-blade sample-prep model, the QuantiFERON-TB franchise, QIAstat-Dx syndromic testing and digital PCR, how it stacks up against Roche, Danaher and Cepheid, bioMerieux and Hologic, plus slower growth and FX risk for US investors.
AtriCure (ATRC) stock outlook 2026: a qualitative deep dive into the surgical Afib ablation and AtriClip left atrial appendage management business, the guideline tailwind driving adoption, why the company still runs a net loss, and the pulsed field ablation competitive threat.
Integra LifeSciences (IART) stock outlook for 2026. A deep qualitative look at its neurosurgery dura replacements and CSF shunts, collagen skin-regeneration matrices, reconstructive portfolio, the niche surgical moat, recall and quality (QC) manufacturing-normalization execution risk, and how it stacks up against SYK, ZBH, and GMED.
NARI (Inari Medical) 2026 stock outlook. A deep qualitative look at the FlowTriever and ClotTriever mechanical thrombectomy franchise, the venous thromboembolism (VTE) TAM and penetration story, competition from Penumbra and Boston Scientific, reimbursement dynamics, and what Stryker's strategic interest means for investors.
Ray Co (228670) 2026 stock outlook. A deep qualitative look at the KOSDAQ digital-dentistry maker of dental CBCT imaging, intraoral scanners and dental 3D printing, its ex-Samsung imaging lineage, global dental DX tailwind, export and FX cycles, and what a foreign investor should weigh before buying a small-cap Korean med-tech name.
MegaGen Implant (KOSDAQ 357550) Stock Outlook 2026. AnyRidge fixture positioning after Osstem's 2023 delisting, R2GATE digital surgical workflow, European and US channel expansion, and the Chinese VBP pricing threat, analyzed qualitatively for foreign investors.
Haemonetics (HAE) stock outlook for 2026: the NexSys plasma razor-and-blade consumables model, CSL and large-customer concentration risk, contract transitions, and the Hospital diversification thesis (TEG hemostasis, vascular closure) with bull, base, and bear scenarios.
CNMD (CONMED) 2026 stock outlook. A qualitative deep dive on AirSeal insufflation, Buffalo Filter surgical smoke evacuation, the orthopedics and sports medicine business, single-use recurring revenue, and the acquisition debt and integration risk that shadow the growth story.
Tandem Diabetes Care (TNDM) 2026 stock outlook. A deep qualitative look at t:slim X2 and Mobi pumps with Control-IQ automation, Dexcom and Abbott CGM integration, pump-replacement and Type-2 expansion TAM, Insulet and Medtronic competition, and the path to sustained profitability and free cash flow from a recurring installed-base supplies model.
GKOS (Glaukos) 2026 stock outlook. A deep qualitative look at its glaucoma MIGS leadership with iStent, the iDose sustained drug-delivery pivot, the Epioxa corneal-disease pipeline, and the reimbursement, competition, and cash-burn growth-stock risks.
PEN (Penumbra) 2026 stock outlook. A qualitative deep dive into aspiration thrombectomy for stroke, peripheral CAVT, the single-use catheter razor-and-blade model, recall and valuation risk, and Stryker and Medtronic competition.
Globus Medical (GMED) 2026 stock analysis: the ExcelsiusGPS razor-blade robotics model, NuVasive merger synergies versus sales-force disruption, trauma and orthopedics expansion, and heavyweight competition from Medtronic and Stryker.
Becton Dickinson (NYSE: BDX) 2026 investment analysis — consumable-driven moat, Dividend Aristocrat track record, portfolio separation strategy, key risks, and how BD stacks up against Stryker, Medtronic, and peers.